We are live on ! Find out more
JSPR icon

Jasper Therapeutics

55 hedge funds and large institutions have $13.9M invested in Jasper Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more call options, than puts

Call options by funds: $110K | Put options by funds: $25K

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

4% more funds holding

Funds holding: 53 → 55 (+2)

12.19% less ownership

Funds ownership: 68.69% → 56.51% (-12%)

46% less capital inflows, than outflows

Capital inflows: $5.61M | Capital outflows: $10.4M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
15
Reduced
13
Closed
9
Calls
$110​K
Puts
$25​K
Net Calls
+$85​K
Net Calls Change
-⁠$297​K

JSPR Hedge Fund Activity: Q1 2026 in Review

55 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2026, worth a combined $13.9M — down 61% from $35.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new JSPR positions and 9 closed out — a net gain of 3 holders — while 15 added to existing stakes and 13 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $1.88M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.2M sold.

  • 55 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2026, up from 53 in Q4 2025.
  • Funds reported $13.9M of Jasper Therapeutics stock for Q1 2026, down 61% quarter-over-quarter.
  • 12 funds opened new Jasper Therapeutics positions in Q1 2026 and 9 closed out, a net change of +3 holders.
  • The largest Jasper Therapeutics buyer in Q1 2026 was Kingdon Capital Management, an estimated $1.88M added.
  • The largest Jasper Therapeutics seller in Q1 2026 was Goldman Sachs, an estimated $3.2M sold.

Based on aggregated 13F filings for Q1 2026.